Outlook Therapeutics announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence. Most recently, Sharma was Senior Medical Director, Cornea, Dry Eye and Retina, Global Medical Affairs at Santen Pharmaceuticals. Prior to joining Outlook Therapeutics, in his role as the VP of Business and New Product Development at Fagron Sterile Services,Olsheim focused on driving revenue, profit and value in repackaging IV bevacizumab for ophthalmic use in retina indications.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OTLK:
- Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
- Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
- Outlook Therapeutics sees funding through FDA approval of ONS-5010
- Outlook Therapeutics announces anticipated milestones